Proteostasis shares zoom north as their cystic fibrosis doublet causes a stir in small study -- triggering an online brawl
Sometimes it’s the smallest studies that gain the biggest reactions from the investment crowd that follows biotech.
Case in point: Little Proteostasis Therapeutics hit big-time pay dirt on Thursday, watching its stock $PTI swoop up 448% on some intriguing early data on a handful of patients suffering from cystic fibrosis.
Breaking 21 patients homozygous for the F508del mutation into various dose groups for their CF doublet therapy, researchers teased out some significant results for the few people in the high dose cohort that was evaluable at the time of the Phase I cutoff for their readout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.